Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Han Zhang, Juan Chen, Ying Zhang, Na Zhao & Dongmei Xu. (2023) Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis. Renal Failure 45:1.
Read now
Read now
Milena Tocut, Yehuda Shoenfeld & Gisele Zandman-Goddard. (2020) Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. Expert Opinion on Investigational Drugs 29:10, pages 1151-1162.
Read now
Read now
Articles from other publishers (17)
Tao Liao, Xiaoyi Shi, Fei Han, Yuchen Wang, Wenli Zeng, Rumin Liu, Ziyan Yan, Renfei Xia, Zhengyu Huang, Jian Xu & Yun miao. (2023) Blockade of BLyS inhibits B cell responses and antibody production for the prevention of chronic transplant rejection. The Journal of Heart and Lung Transplantation.
Crossref
Crossref
Lubna Abuqayyas, Po‐Wei Chen, Marcia Teixeira dos Santos, Jane R. Parnes, Sameer Doshi, Sandeep Dutta & Brett E. Houk. (2023)
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of
BAFF
and
ICOSL
: Analyses of Phase I Clinical Trials
. Clinical Pharmacology & Therapeutics 114:2, pages 371-380.
Crossref
Crossref
Kai Zhang, Tiening Qi, Donghua Guo & Youxia Liu. (2023) Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta‐analysis and a propensity score‐matched case–control study. Immunity, Inflammation and Disease 11:7.
Crossref
Crossref
Elham Daneshvar, Soheil Tavakolpour, Hamidreza Mahmoudi, Maryam Daneshpazhooh, Amir Teimourpour, Saeed Aslani & Kamran Balighi. (2022)
Elevated serum level of B‐cell activating factor (
BAFF
) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B‐cell depletion therapies combined with
anti‐BAFF
agents
. International Journal of Dermatology 62:4, pages 567-574.
Crossref
Crossref
Mirjam Kolev, Adela-Cristina Sarbu, Burkhard Möller, Britta Maurer, Florian Kollert & Nasser Semmo. (2023) Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis – a case series. Journal of Translational Autoimmunity 6, pages 100189.
Crossref
Crossref
Nuntana Kasitanon, Laniyati Hamijoyo, Meng Tao Li, Kenji Oku, Sandra Navarra, Yoshiya Tanaka & Chi Chiu Mok. (2022)
Management of non‐renal manifestations of systemic lupus erythematosus: A systematic literature review for the
APLAR
consensus statements
. International Journal of Rheumatic Diseases 25:11, pages 1220-1229.
Crossref
Crossref
Albert J. Czaja. (2022) Advancing Biologic Therapy for Refractory Autoimmune Hepatitis. Digestive Diseases and Sciences 67:11, pages 4979-5005.
Crossref
Crossref
Erika L. Hubbard, Amrie C. Grammer & Peter E. Lipsky. (2021) Transcriptomics data: pointing the way to subclassification and personalized medicine in systemic lupus erythematosus. Current Opinion in Rheumatology 33:6, pages 579-585.
Crossref
Crossref
Wenhui Xie, Hong Huang, Siyan Zhan & Zhuoli Zhang. (2021) Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials. Lupus Science & Medicine 8:1, pages e000534.
Crossref
Crossref
Albert J. Czaja. (2021) Review article: targeting the B cell activation system in autoimmune hepatitis. Alimentary Pharmacology & Therapeutics 54:7, pages 902-922.
Crossref
Crossref
E. L. Nasonov, T. V. Popkova & A. M. Lila. (2021) Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Rheumatology Science and Practice 59:4, pages 367-383.
Crossref
Crossref
Shirley Chiu Wai Chan & Chak Sing Lau. (2021) Systemic lupus erythematosus and immunodeficiency. Rheumatology and Immunology Research 2:3, pages 131-138.
Crossref
Crossref
Mahya Eslami & Pascal Schneider. (2021) Function, occurrence and inhibition of different forms of BAFF. Current Opinion in Immunology 71, pages 75-80.
Crossref
Crossref
Joan T Merrill. (2021) Systemic lupus erythematosus: diverting progress to chase rare side effects?. The Lancet Rheumatology 3:2, pages e87-e88.
Crossref
Crossref
Emma J. Keller, Neeva B. Patel, Madeline Patt, Jane K. Nguyen & Trine N. Jørgensen. (2021) Partial Protection From Lupus-Like Disease by B-Cell Specific Type I Interferon Receptor Deficiency. Frontiers in Immunology 11.
Crossref
Crossref
Margarida Matos Bela, Gerard Espinosa & Ricard Cervera. (2020) Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy. Lupus 30:1, pages 134-140.
Crossref
Crossref
Sadettin Uslu. (2021) Shrinking Lung Syndrome Caused by Systemic Lupus Erythematosus: a Case Report. SN Comprehensive Clinical Medicine 3:1, pages 297-299.
Crossref
Crossref